La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Halozyme Therapeutics Croissance future

Future contrôle des critères 5/6

Halozyme Therapeutics is forecast to grow earnings and revenue by 22% and 15.6% per annum respectively. EPS is expected to grow by 24% per annum. Return on equity is forecast to be 83.1% in 3 years.

Informations clés

22.0%

Taux de croissance des bénéfices

24.0%

Taux de croissance du BPA

Biotechs croissance des bénéfices	30.4%
Taux de croissance des recettes	15.6%
Rendement futur des capitaux propres	83.1%
Couverture par les analystes	Good
Dernière mise à jour	07 Aug 2024

Mises à jour récentes de la croissance future

Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Feb 23

Recent updates

Halozyme Therapeutics, Inc.: Significantly Undervalued Growth Based On Current Fundamentals

Aug 14

Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Feb 23

Halozyme Therapeutics: A Reasonable Value In An Overvalued Market

Jan 26

These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely

Jan 10

Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price

Dec 14

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Sep 22

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate

Jul 04

We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt

May 09

Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?

Mar 28

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Jan 23

Calculating The Intrinsic Value Of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Dec 09

Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?

Oct 24

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:HALO - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	1,400	678	N/A	N/A	6
12/31/2025	1,145	512	627	633	9
12/31/2024	984	416	536	528	10
6/30/2024	873	337	408	420	N/A
3/31/2024	863	319	424	431	N/A
12/31/2023	829	282	373	389	N/A
9/30/2023	781	254	354	369	N/A
6/30/2023	774	234	293	306	N/A
3/31/2023	705	182	264	279	N/A
12/31/2022	660	202	235	240	N/A
9/30/2022	581	211	238	240	N/A
6/30/2022	487	366	290	292	N/A
3/31/2022	472	435	287	289	N/A
12/31/2021	443	403	298	299	N/A
9/30/2021	463	409	265	268	N/A
6/30/2021	412	229	150	152	N/A
3/31/2021	331	163	116	119	N/A
12/31/2020	268	129	53	55	N/A
9/30/2020	200	22	-24	-22	N/A
6/30/2020	180	-40	-60	-58	N/A
3/31/2020	164	-80	-89	-86	N/A
12/31/2019	196	-72	-89	-85	N/A
9/30/2019	203	-40	-55	-48	N/A
6/30/2019	182	-43	-43	-38	N/A
3/31/2019	178	-51	-36	-32	N/A
12/31/2018	152	-80	-54	-49	N/A
9/30/2018	281	46	91	93	N/A
6/30/2018	319	76	130	132	N/A
3/31/2018	318	68	N/A	134	N/A
12/31/2017	317	63	N/A	134	N/A
9/30/2017	166	-88	N/A	-35	N/A
6/30/2017	134	-120	N/A	-64	N/A
3/31/2017	134	-116	N/A	-60	N/A
12/31/2016	147	-103	N/A	-50	N/A
9/30/2016	160	-71	N/A	-50	N/A
6/30/2016	149	-67	N/A	-58	N/A
3/31/2016	159	-37	N/A	-36	N/A
12/31/2015	135	-32	N/A	-37	N/A
9/30/2015	113	-42	N/A	-23	N/A
6/30/2015	107	-38	N/A	-19	N/A
3/31/2015	82	-57	N/A	-44	N/A
12/31/2014	75	-68	N/A	-48	N/A
9/30/2014	57	-85	N/A	-62	N/A
6/30/2014	59	-84	N/A	-61	N/A
3/31/2014	55	-91	N/A	-56	N/A
12/31/2013	55	-83	N/A	-49	N/A
9/30/2013	64	-66	N/A	-51	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: HALO's forecast earnings growth (22% per year) is above the savings rate (2.5%).

Bénéfices vs marché: HALO's earnings (22% per year) are forecast to grow faster than the US market (15.1% per year).

Croissance élevée des bénéfices: HALO's earnings are expected to grow significantly over the next 3 years.

Chiffre d'affaires vs marché: HALO's revenue (15.6% per year) is forecast to grow faster than the US market (8.8% per year).

Croissance élevée des revenus: HALO's revenue (15.6% per year) is forecast to grow slower than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: HALO's Return on Equity is forecast to be very high in 3 years time (83.1%).

Halozyme Therapeutics Croissance future

Future contrôle des critères 5/6

Informations clés

Mises à jour récentes de la croissance future

Halozyme Therapeutics, Inc. Reiterates Financial Guidance for 2024

Price target increased by 11% to US$57.11

Halozyme Therapeutics, Inc. Updates Earnings Guidance for the Full Year 2024

Price target increased by 8.3% to US$51.44

Halozyme Therapeutics, Inc. Reiterates Revenue Guidance for 2024

Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Recent updates

Independent Director recently sold US$1.7m worth of stock

Halozyme Therapeutics, Inc.: Significantly Undervalued Growth Based On Current Fundamentals

Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Halozyme Therapeutics, Inc. Reiterates Financial Guidance for 2024

Senior VP & CTO notifies of intention to sell stock

Halozyme Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Not Flying Under The Radar

Senior VP & CFO notifies of intention to sell stock

Halozyme Therapeutics, Inc. Announces Roche's OCREVUS SC with ENHANZE Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis

Halozyme Therapeutics, Inc. Announces argenx Receives FDA Approval for VYVGART Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy

Independent Director recently sold US$1.0m worth of stock

Independent Director notifies of intention to sell stock

Price target increased by 11% to US$57.11

Halozyme Therapeutics, Inc. Updates Earnings Guidance for the Full Year 2024

Halozyme Therapeutics: The Story Brightens

Investor sentiment improves as stock rises 19%

Senior VP & CTO exercised options and sold US$743k worth of stock

Price target increased by 8.3% to US$51.44

Halozyme Therapeutics, Inc. Reiterates Revenue Guidance for 2024

Halozyme Therapeutics, Inc. Announces the Election of Mahesh Krishnan, M.D. to its Board of Directors

Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?

Halozyme Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Senior VP & Chief Technical Officer exercised options and sold US$606k worth of stock

Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics

Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?

Halozyme Therapeutics, Inc., Annual General Meeting, Apr 25, 2024

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares

Senior VP & Chief Technical Officer exercised options and sold US$612k worth of stock

Senior VP & Chief Technical Officer notifies of intention to sell stock

Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Full year 2023 earnings: EPS exceeds analyst expectations

President exercised options and sold US$735k worth of stock

Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

President exercised options and sold US$601k worth of stock

Halozyme Therapeutics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Halozyme Therapeutics: A Reasonable Value In An Overvalued Market

Halozyme Announces Argenx Receives Approval in Japan for Vyvdura®? Co-Formulated with Enhanze®? for Generalized Myasthenia Gravis

Senior VP & Chief Technical Officer notifies of intention to sell stock

Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Twelve Months Ended December 31, 2023

Halozyme Announces Takeda Receives FDA Approval for Hyqvia® Co-Formulated with Enhanze® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy

Halozyme Announces Roche Receives European Commission Approval of Tecentriq®? SC with ENHANZE®? Representing the EU's First Subcutaneous PD(L)1 Cancer Immunotherapy for Multiple Cancer Types

These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely

Senior VP & Chief Technical Officer exercised options and sold US$544k worth of stock

Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price

Senior VP & Chief Technical Officer notifies of intention to sell stock

Third quarter 2023 earnings: EPS exceeds analyst expectations

Halozyme Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Halozyme Therapeutics, Inc. Reports Positive Topline Results from the Phase 3 Checkmate-67T Trial Evaluating Subcutaneous (SC) Formulation of Opdivo (Nivolumab) with Enhanze

Senior VP & Chief Technical Officer notifies of intention to sell stock

Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Senior VP & Chief Technical Officer notifies of intention to sell stock

Halozyme Therapeutics, Inc Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain

Independent Director recently sold US$875k worth of stock

Independent Director notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Full Year 2023

Halozyme Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Senior VP & Chief Technical Officer notifies of intention to sell stock

Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Positive Results Announces from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate

Senior VP & Chief Technical Officer notifies of intention to sell stock

Halozyme Announces argenx Receives FDA Approval for VYVGART Hytrulo With ENHANZE for Subcutaneous Use in Generalized Myasthenia Gravis

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Halozyme Therapeutics, Inc. Reiterates Revenue Guidance for the Full Year 2023

We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt

Senior VP & Chief Technical Officer notifies of intention to sell stock